News
CRDF
0.8801
-3.15%
-0.0286
Cardiff Oncology downgraded to Market Perform from Outperform at William Blair
TipRanks · 6d ago
Weekly Report: what happened at CRDF last week (0810-0814)?
Weekly Report · 6d ago
Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts
TipRanks · 08/15 09:01
Cardiff Oncology Cut to Market Perform From Outperform by William Blair
Dow Jones · 08/12 19:13
William Blair Downgrades Cardiff Oncology to Market Perform
Benzinga · 08/12 19:03
Cardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27
NASDAQ · 08/12 12:55
Piper Sandler Remains a Buy on Cardiff Oncology (CRDF)
TipRanks · 08/12 11:06
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)
TipRanks · 08/11 23:20
William Blair downgrades Cardiff Oncology (CRDF) to a Hold
TipRanks · 08/11 22:25
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/11 21:06
Cardiff Oncology GAAP EPS of -$0.14 beats by $0.02, revenue of $0.1M beats by $0.04M
Seeking Alpha · 08/11 20:27
*Cardiff Oncology 2Q Loss/Shr 14c >CRDF
Dow Jones · 08/11 20:10
Press Release: Cardiff Oncology Reports Second -2-
Dow Jones · 08/11 20:10
Press Release: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Dow Jones · 08/11 20:10
Cardiff Oncology: Q2 Earnings Snapshot
Barchart · 08/11 15:46
Weekly Report: what happened at CRDF last week (0803-0807)?
Weekly Report · 08/10 10:17
Weekly Report: what happened at CRDF last week (0727-0731)?
Weekly Report · 08/03 10:16
Weekly Report: what happened at CRDF last week (0720-0724)?
Weekly Report · 07/27 10:21
Weekly Report: what happened at CRDF last week (0713-0717)?
Weekly Report · 07/20 10:17
Friday 7/17 Insider Buying Report: CRDF, FIS
NASDAQ · 07/17 15:43
More
Webull provides a variety of real-time CRDF stock news. You can receive the latest news about Cardiff Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.